Novel Delivery Systems for Interferons

REFERENCES

• Akerman M. E., Chan W. C. W., Laakkonen P., Bhatia S. N., Ruoslahti E. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA 2002; 99: 12617–12621
   PubMed Web of Science ®Google Scholar
• Algranati N. E., Sy S., Modi M. A branched methoxy 40 kDa poly- ethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α -2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999; 30: 190A, (4 pt 2)
   Google Scholar
• Amsden B., Cheng Y. L. A generic protein delivery system based on osmotically rupturable monoliths. J. Control. Release 1995; 33: 99–105
   Web of Science ®Google Scholar
• Atkinson E. M., Klum W. Formulation strategies for biopharmaceuticals ensuring success to market. IDrugs 2001; 4(5)557–560
   PubMedGoogle Scholar
• Backer D. E. PEGylated interferons. Rev. Gastroenterol. Dis. 2001; 1(2)87–99
   PubMedGoogle Scholar
• Bailon P., Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1998; 1: 352–356
   Google Scholar
• Balan V., Nelson D. R., Sulkowski M. S., Everson G. T., Lambiase L. R., Wiesner R. H., Dickson R. C., Post A. B., Redfield R. R., Davis G. L., Neumann A. U., Osborn B. L., Freimuth W. W., Subramanian G. M. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir. Ther. 2006; 11(1)35–45
   PubMedGoogle Scholar
• Balan V., Sulkowski M. S., Nelson D. R., Everson G. T., Bambury T., Recta J., Zhong J., Mesghali H., Murray J., Osborn B. L., Novello L., Freimuth W. W., Subramanian G. M. A phase 1/2 study to evaluate the pharmacokinetic, safety, tolerability, immunogenicity, and pharmacodynamics of Albuferon in treatment experienced subjects with Chronic Hepatitis C. 53rd Annual Meeting of the American Association for the study of Liver Diseases, Boston, November, 3, 2002, Poster 490
   Google Scholar
• Banker G. S., Rhodes C. T. Target-oriented drug-delivery systems. Modern Pharmaceutics 4th Edition. Marcel Decker Inc., New York 2002; 529–585, Chapter 16
   Google Scholar
• Brannon-Peppas L., Blanchette J. O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004; 56: 1649–1659
   PubMed Web of Science ®Google Scholar
• Bukowski R. M., Tendler C., Cutler D., Rose E., Laughlin M. M., Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 2002; 95(2)389–396
   PubMedGoogle Scholar
• Camma C., Di Bona D., Schepis F., Heathcote E. J., Zeuzem S., Pockros P. J., Maecellin P., Balart L., Alberti A., Craxi A. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39(2)333–342
   PubMedGoogle Scholar
• Chatelut E., Rostaing L., Gregoire N., Payen J. L., Pujol A., Izopet J., Houin G., Canal P. A pharmacokinetic model for alpha interferon administered subcutaneously. British J. Clin. Pharmacol. 1999; 47: 365–371
   PubMed Web of Science ®Google Scholar
• Chieux V., Hober D., Chehadel W., Walter P. Alpha interferon, antiviral proteins and their value in clinical medicine. Ann. Biol. Clin. (Paris) 1999; 57(6)659–666
   PubMedGoogle Scholar
• Choueiri T. K., Hutson T. E., Bukowski R. M. Evolving role of pegylated interferons in metastatic renal cell carcinoma. Exp. Rev. Anticancer Ther. 2003; 3(6)823–829
   PubMedGoogle Scholar
• Cleland J. L., Jones A. J. S. Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable microspheres. Pharm. Res. 1996; 13: 1462–1473
   Google Scholar
• Cohen H., Levy R. J., Gao J., Fishbein I., Kousaev V., Sosnowski S., Slomkowski S., Golomb G. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther. 2000; 7(22)1896–1905
   PubMed Web of Science ®Google Scholar
• Cooksley W. G., Piratvisuth T., Lee S. D., Mahachai V., Chao Y. C., Tanwandee T., Chutaputti A., Chang W. Y., Zahm F. E., Pluck N. Peginterferon alphs-2a (40 kDa): an advance in the treatment of hepatitis B antigen-positive chronic hepatitis B. J. Viral Hepat. 2003; 10(4)298–305
   PubMed Web of Science ®Google Scholar
• Coradini D., Pellizzaro C., Biffi A., Lombardi L., Pirronello E., Riva L., Di Fronzo G. Effect of liposome-encapsulated alpha- or beta-interferon on breast cancer cell lines. Anticancer Res. 1998; 18(1A)177–182
   PubMedGoogle Scholar
• Craxi A., Cooksley W. G. Pegylated interferons for chronic hepatitis B. Antiviral Res. 2003; 60(2)87–89
   PubMed Web of Science ®Google Scholar
• Crommelin D. J., Sindelar R. D. Pharmaceutical Biotechnology, 2nd ed. Taylor and Francis, New York 2002; 217–230
   Google Scholar
• Crommelin D. J., Storm G., Verrijk R., de Leede L., Jiskoot W., Hennink W. E. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int. J. Pharm. 2003; 266(1–2)3–16
   PubMedGoogle Scholar
• Davis S. S. Delivery systems for biopharmaceuticals. J. Pharm. Pharmacol. 1992; 44: 186–190, (Suppl. 1)
   PubMed Web of Science ®Google Scholar
• Davis G. L., Wong J. B., McHutchison J. G., Manns M. P., Harvey J., Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38(3)645–652
   PubMed Web of Science ®Google Scholar
• Davis F. F., Abuchowski A., Van E S. T. Enzyme-polyethylene glycol adducts: modified enzymes with unique properties. Enzyme Eng. 1978; 4: 169–173
   Google Scholar
• De Plessis J., Egbaria K., Ramachandran C., Weiner N. Topical delivery of liposomally encapsulated gamma-interferon. Antiviral Res. 1992; 18(3–4)259–265
   PubMedGoogle Scholar
• Diwan M., Park T. G. Stabilization of recombinant interferon-alpha by pegylation for encapsulation in PLGA microspheres. Int. J. Pharm. 2003; 252(1–2)111–122
   PubMed Web of Science ®Google Scholar
• Du S. L., Wang J. Y., Pan H., Lu W. Y., Wang J. Antifibrotic effects of cyclic RGD-peptide mediated liposomal interferon: an experimental on rats. Zhonghua Yi. Xue. Za. Zhi 2005; 85(15)1015–1020
   PubMedGoogle Scholar
• Egbaria K., Ramachandran C., Kittayanond D., Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob. Agents Chemother. 1990; 34(1)107–110
   PubMedGoogle Scholar
• Eppstein D. A. Altered pharmacologic properties of liposome-associated human interferon-alpha. II. J. Interferon Res. 1982; 2(1)117–125
   PubMedGoogle Scholar
• Eppstein D. A., Stewart W. E. Altered pharmacological properties of liposome-associated human interferon-alpha. J. Virol. 1982; 41(2)575–582
   PubMedGoogle Scholar
• Eppstein D. A., Marsh Y. V., van der Pas M., Felgner P. L., Schreiber A. B. Biologic activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. Proc. Natl. Acad. Sci. USA 1985; 82(11)3688–3692
   PubMedGoogle Scholar
• Eppstein D. A., van der Pas M., Gloff C. A., Soike K. F. Liposomal interferon-beta: sustained release treatment of simian varicella virus infection in monkeys. J. of Infect. Dis. 1989; 159(4)616–620
   PubMedGoogle Scholar
• Eyles J. E., Alpar H. O., Conway B. R., Keswick M. Oral delivery and fate of poly (lactic acid) microsphere-encapsulated interferon in rats. J. Pharm. Pharmacol. 1997; 49(7)669–674
   PubMed Web of Science ®Google Scholar
• Faulkner L., Buchan G., Slobbe L., Lockhart E., Wales J., Wilson M., Baird M. Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection. Vaccine 2003; 21(9–10)932–939
   PubMed Web of Science ®Google Scholar
• Formann E., Jessner W., Bennett L., Ferenci P. Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J. Viral Hepatitis 2003; 10(4)271–276
   PubMed Web of Science ®Google Scholar
• Fujioka K., Maeda M., Hojo T., Sano A. Protein release from collagen matrices. Adv. Drug Deliv. Rev. 1998; 31: 247–266
   PubMed Web of Science ®Google Scholar
• Fujioka K., Takada Y., Sato S., Miyata T. Novel delivery system for proteins using collagen as a carrier material: The minipellet. J. Control. Release 1995a; 33: 307–315
   Web of Science ®Google Scholar
• Fujioka K., Takada Y., Sato S., Miyata T. Long-acting delivery system of interferon: IFN minipellet. J. Control. Release 1995b; 33: 317–323
   Web of Science ®Google Scholar
• Gaertner F. H., Babiuk L. A., Van Moorlehem E. A., Beskorwayne T. K., Lee S. L., Shutter R. W., Armstrong J. M., Griebel P. J. Amended recombinant cells (ARCs): an economical and surprisingly effective protection and delivery vehicle for recombinant bovine IFN-gamma. J. Control. Release 2005; 107(2)189–202
   PubMedGoogle Scholar
• Ghahary A., Shen Q., Rogers J. A., Wang R., Fathi-Afshar A., Scott P. G., Tredget E. E. Liposome-associated interferon-alpha-2b functions as an anti-fibrogenic factor for human dermal fibroblasts. J. Invest. Dermatol. 1997; 109(1)55–60
   PubMedGoogle Scholar
• Ghahary A., Tredget E. E., Shen Q., Kilani R. T., Scott P. G., Takeuchi M. Liposome associated interferon-alpha-2b functions as an antifibrogenic factor in dermal wounds in the guinea pig. Mol. Cell. Biochemist. 2000; 208(1–2)129–137
   PubMedGoogle Scholar
• Glue P., Fang J. W. S., Rouzier-Panis R., Faffanel C., Sabo R., Gupta S. K., Salfi M., Jacobs S. Pegylated interferon α 2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Therapeutics. 2000; 68: 556–567
   PubMed Web of Science ®Google Scholar
• Liposome Technology 2nd ed., G. Gregoriadis. CRC Press, Boca Raton, FL 1993; vol. 1–3
   Google Scholar
• Gresser I., Belardelli F. Endogenous type I interferon as a defence against tumor. Cytokine Growth Factor Rev. 2002; 13(2)111–118
   PubMedGoogle Scholar
• Gu F., Younes H. M., El-Kadi A. O. S., Neufeld R. J., Amsden B. G. Sustained interferon-γ delivery from a photocrosslinked biodegradable elastomer. J. Control. Release 2005; 102: 607–617
   PubMed Web of Science ®Google Scholar
• Hadziyannis S. J., Sette H. J., Morgan T. R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer H. J., Bernstein D., Rizzetto M., Zeuzem S., Pockros P. J., Ackrill A. M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Int. Med. 2004; 140(5)346–355
   PubMed Web of Science ®Google Scholar
• Hamidi M., Tajerzadeh H. Carrier erythrocytes: An overview. Drug Deliv. 2003; 10: 9–20
   PubMed Web of Science ®Google Scholar
• Hamidi M., Azadi A., Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv. 2006; 13: 1–11
   PubMedGoogle Scholar
• Hamidi M., Zarei N., Zarrin A. H., Mohammadi-Samani S. Preparation and in vitro characterization of carrier erythrocytes for vaccine delivery. Int. J. Pharm. 2007a, 2007, Jan 20; epub ahead of print – update
   Google Scholar
• Hamidi M., Zarrin A. H., Foroozesh M., Zarei N., Mohammadi-Samani S. Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b. Int. J. Pharm. 2007b, 2007, Apr 6; Epub ahead of print – update
   Google Scholar
• Hanada T., Yoshimura A. Regulation of cytokine signalling and inflammation. Cytokine Growth factor Rev. 2002; 3(4–5)413–421
   Google Scholar
• Harris M., Martin N. E., Modi M. PEGylation: A novel process for modifying pharmacokinetics. Clin. Pharmacokinetics 2001; 40(7)539–551
   PubMed Web of Science ®Google Scholar
• Herrmann J., Stricker H. Interferon-γ liposomes: Drug binding properties and antiviral in vitro activity. Eur. J. Pharm. Biopharm. 1995; 41(6)361–368
   Google Scholar
• Hofer C., Gobel R., Deering P., Lehmer A., Bruel J. Formulation of interleukine-2 and interferon-alpha containing ultra-deformable carriers for potential transdermal application. Anticancer Res. 1999; 19(2C)1505–1507
   PubMedGoogle Scholar
• Hofer C., Hartung R., Gobel R., Deering P., Lehmer A., Bruel J. New ultra-deformable drug carriers for potential transdermal application of interleukin-2 and interferon-alpha: theoretic and practical aspects. World J. Surg. 2000; 24(10)1187–1189
   PubMedGoogle Scholar
• Howell S. B. Clinical applications of a novel sustained-release injectable drug delivery system: Depofoam technology. Cancer J. 2001; 7(3)219–227
   PubMed Web of Science ®Google Scholar
• Huber C. H., Wolfel T. Immunotherapy of cancer: from vision to standard clinical practice. J. Cancer Res. Clin. Oncol. 2004; 130(7)367–374
   PubMedGoogle Scholar
• Jaitely V., Kanaujia P., Venkatesan N., Jain S., Vyas S. P. Resealed erythrocytes: Drug carrier potentials and biomedical applications. Ind. Drugs 1996; 33: 589–549
   Google Scholar
• Jonah M. M., Cerny E. A., Rahman Y. E. Tissue distribution of EDTA encapsulated within liposomes of varying surface properties. Biochim. Biophys. Acta 1975; 401: 336–348
   PubMed Web of Science ®Google Scholar
• Jonasch E., Haluska F. G. Interferon in oncological practice: review of interferon biology, clinical application, and toxicities. Oncologist 2001; 6(1)34–55
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Stamp D., McCullough N. Pharmacokinetics of liposome-encapsulated antitumor drugs and implications for therapy. Ann. New York Acad. Sci. 1978; 308: 411–423
   PubMedGoogle Scholar
• Kadowaki N., Antonenko S., Lau J. Y., Liu Y. J. Natural interferon alpha/beta-producing cells link innate and adoptive immunity. J. Exp. Med. 2000; 192(2)219–226
   PubMedGoogle Scholar
• Kajihara M., Sugie T., Hojo T., Maeda H., Sano A., Fujioka K., Sugawara S., Urabe Y. Development of a new drug delivery system for protein drugs using silicone (II). J. Control. Release 2001; 73(2–3)279–291
   PubMed Web of Science ®Google Scholar
• Kajihara M., Sugie T., Mizuno M., Tamura N., Sano A., Fujioka K., Kashiwazaki Y., Yamaoka T., Sugawara S., Urabe Y. Development of new drug delivery system for protein drugs using silicone (I). J. Control. Release 2000; 66(1)49–61
   PubMed Web of Science ®Google Scholar
• Kalenik T. N., Motavkina N. S., Vorob'ev A. A. Liposome-incorporated interferon: The design of liposomal interferon. Zhurnal Mikrobiologii Epidemiologii Immunobiologii 1999; 3: 55–58
   Google Scholar
• Kanaoka E., Nagata S., Hirano K. Stabilization of aerosolized IFN-gamma by liposomes. Int. J. Pharm. 1999; 188(2)165–172
   PubMedGoogle Scholar
• Kaparissides C., Alexandridou S., Kotti K., Chaitidou S. Recent advances in novel drug delivery systems. AZojono 2006; 111(2)1–11
   Google Scholar
• Karau C., Petszulat M., Schmidt P. C. Preparation and stability of interferon-α -containing liposomes. Int. J. Pharm. 1996; 128: 89–98
   Web of Science ®Google Scholar
• Kataoka T., Kobayashi T. Enhancement of chemotherapeutic effect by entrapping 1-β -D-arabinofuranosylcytosine in lipid vesicles and its mode of action. Ann. New York Acad. Sci 1978; 308: 387–394
   PubMedGoogle Scholar
• Killion J. J., Fan D., Bucana C. D., Frangos D. N., Price J. E., Fidler I. J. Augmentation of antiproliferative activity of interferon alfa against human bladder tumor cell lines by encapsulation of interferon alfa within liposomes. J. Natl. Cancer Inst. 1989; 81: 1387–1392
   PubMed Web of Science ®Google Scholar
• Kimelberg H. K., Atchison M. L. Effects of entrapment in liposomes on the distribution, degradation, and effectiveness of methotrexate in vivo. Ann. New York Acad. Sci 1978; 308: 395–409
   PubMedGoogle Scholar
• Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin. Oncol. 2002; 29: 18–26, (3 supp 17)
   PubMed Web of Science ®Google Scholar
• Kishimoto T., Taga T., Akira S. H. Cytokine signal transduction. Cell 1994; 76: 253–262
   PubMed Web of Science ®Google Scholar
• Kontsek P., Karayianni-Vasconcelos G., Konteskora E. The human interferon system: characterization and classification after discovery of novel numbers. Acta Virologica 2003; 47(4)201–215
   PubMedGoogle Scholar
• LaVan D. A., McGuire T., Langer R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 2003; 21(10)1184–1191
   PubMed Web of Science ®Google Scholar
• Lee J. P., Jalili R. B., Tredget E. E., Demare J. R., Ghahary A. Antifibrogenic effects of liposome-encapsulated IFN-alpha2b cream on skin wounds in a fibrotic rabbit ear model. J. Interferon Cytokine Res. 2005; 25(10)627–631
   PubMedGoogle Scholar
• Lesinski G. B., Sharma S., Varker K. A., Sinha P., Ferrari M., Carson W. E. Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed. Microdevices 2005; 7(1)71–79
   PubMedGoogle Scholar
• Marumo K., Oya M., Murai M. Application of the interferon minipellet to human renal cell carcinoma in nude mice. Int. J. Urol. 1997; 4(1)55–61
   PubMedGoogle Scholar
• Masci P., Bukowski R. M., Patten P. A., Osborn B. L., Borden E. C. New and modified interferon alfas: preclinical and clinical data. Curr. Oncol. Rep. 2003; 5(2)108–113
   PubMedGoogle Scholar
• Mayhew E., Rustum Y. M., Szoka F., Papahadjopoulos D. Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes. Cancer Treat. Rep. 1979; 63: 1923–1928
   PubMedGoogle Scholar
• Mayhew E., Papahadjopoulos D., Rustum Y. M., Chandrakant D. Use of liposomes for enhancement of the cytotoxic effects of cytosine arabinoside. Ann. New York Acad. Sci 1978; 308: 371–386
   PubMedGoogle Scholar
• McCormick A. L., Thomas M. S., Heath A. W. Immunization with an interferon-gamma-gp120 fusion protein induces immune responses to human immunodeficiency virus gp120. J. Infect. Dis. 2001; 184(11)1423–1430
   PubMedGoogle Scholar
• McHutchison J. G., Freid M. W. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin. Liver Dis. 2003; 7(1)149–161
   PubMedGoogle Scholar
• Mehta C., Thanoo B. C., Deluca P. P. Peptide containing microspheres from low molecular weight and hydrophilic poly (d, l-lactide-co-glycolide). J. Control. Release 1996; 41: 249–257
   Web of Science ®Google Scholar
• Melissen P. M., van Vianen W., Bidjai O., van Marion M., Bakker-Woudenberg I. A. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (MTPPE) and interferon-γ (IFN-γ) in experimental infection with Listeria monocytogenes. Biotherapy 1993; 6(2)113–124
   PubMedGoogle Scholar
• Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., Rake J., Shaw J. M., Pugh S., Polin L., Jones J., Corbett T., Cooper E., Liversidge G. G. Formulation and antitumor activity evaluation of nano crystalline suspensions of poorly soluble anticancer agents. Pharm. Res. 1996; 13(2)272–278
   PubMedGoogle Scholar
• Michallet M., Maloisel F., Delain M., Hellmann A., Rosas A., Silver R. T., Tendler C. Pegylated recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18(2)309–315
   PubMed Web of Science ®Google Scholar
• Middaugh C. R. Formulation and delivery of biopharmaceuticals. J. Pharm. Sci. 1996; 85(12)1259–1260
   PubMedGoogle Scholar
• Mizokami M. M., Hu P., Khawli L. A., Li J., Epstein A. L. Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies. Hybrid. Hybridomics 2003; 22(4)197–207
   PubMedGoogle Scholar
• Mohl S., Winter G. Continuous release of rh-interferon-alpha-2a from triglyceride matrices. J. Control. Release 2004; 97(1)67–78
   PubMedGoogle Scholar
• Molineux G. PEGylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. 2002; 28: 13–16, (Suppl. A)
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Rakhit A., Ginsberg M., Rittweger K., Vuky J., Yu R., Fettner S., Hooftman L. Phase I trial of 40-kDa branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J. Clin. Oncol. 2001; 19(5)1312–1319
   PubMed Web of Science ®Google Scholar
• Motzer R. J., Rakhit A., Thopmpson J., Gurney H., Selby P., Figlin R., Negrier S., Ernst S., Siebels M., Ginsberg M., Rittweger K., Hoofman L. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann. Oncol. 2002; 13(11)1799–1805
   PubMed Web of Science ®Google Scholar
• Niemiec S. M., Ramachandran C., Weiner N. Influence of nonionic liposomal composition on topical delivery of peptide drugs into pilosebaceous units: an in vivo study using the hamster ear model. Pharm. Res. 1995; 12(8)1184–1188
   PubMed Web of Science ®Google Scholar
• Okamoto M., Gohda H., Ohe G., Yoshida H., Saito M., Sato M. Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation. J. Immunother. 2000; 23(1)94–103
   PubMedGoogle Scholar
• Orive G., Gascon A. R., Hernanclez R. M., Dominguez-Gil A., Pedraz J. L. Techniques: New approaches to the delivery of biopharmaceuticals. Trends Pharmacol. Sci. 2004; 25(7)382–387
   PubMed Web of Science ®Google Scholar
• Osborn B. L., Olsen H. S., Nardelli B., Murray J. H., Zhou J. X., Garcia A., Moody G., Zaritskaya L. S., Sung C. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 2002; 303(2)540–548
   PubMed Web of Science ®Google Scholar
• Ozzello L., Blank E. W., De Rosa C. M., Ceriani R. L., Tolo H., Kauppinen H. L., Cantell K. Conjugation of interferon alpha to a humanized monoclonal antibody (HuBrE-3vl) enhances the selective localization and antitumor effects of interferon in breast cancer xenografts. Breast Cancer Res. Treat. 1998; 46(2)135–147
   Google Scholar
• Pedder S. C. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin. Liver Dis. 2003; 23: 19–22, (Suppl. 1)
   PubMed Web of Science ®Google Scholar
• Pepinsky R. B., Lepage D. J., Gill A., Chakraborty A., Vaidyanathan S., Green M., Baker D. P., Whalley E., Hochman P. S., Martin P. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 2001; 297(3)1059–1066
   PubMed Web of Science ®Google Scholar
• Peppas N. A., Langer R. New challenges in biomaterials. Science 1994; 263(5154)1715–1720
   PubMed Web of Science ®Google Scholar
• Pettit D. K., Gombotz W. R. The development of site-specific drug delivery systems for protein and peptide biopharmaceuticals. Trends Biotechnol. 1998; 16(8)343–349
   PubMedGoogle Scholar
• Qiu J., Wei X. H., Geng F., Liu R., Zhang J. W., Xu Y. H. Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b. Acta Pharmacol. Sin. 2005; 26(11)1395–1401
   PubMed Web of Science ®Google Scholar
• Rader R. A. What is a biopharmaceutical? Part 1. BioExecutive International 2005; 60–65, March
   Google Scholar
• Ravi-Kumar M. N. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharmaceu. Sci. 2000; 3(2)234–258
   PubMedGoogle Scholar
• Reddy K. R. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 2000; 34: 915–923
   PubMed Web of Science ®Google Scholar
• Rutenfranz I., Bauer A., Kirchner H. Pharmacokinetic study of liposome-encapsulated human interferon-gamma after intravenous and intramuscular injection in mice. J. Interferon Res. 1990; 10(3)337–341
   PubMedGoogle Scholar
• Sahoo S. K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today 2003; 24(8)1112–1120
   Google Scholar
• Sanchez A., Tobio M., Gonzalez L., Fabra A., Alonso M. J. Biodegradable micro-and-nanoparticles as long-term delivery vehicles for interferon-alpha. Eur. J. Pharm. Sci. 2003; 18(3–4)221–229
   PubMed Web of Science ®Google Scholar
• Saravolac E. G., Kournikakis B., Gorton L., Wong J. P. Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-gamma 1. Antiviral Res. 1996; 29(2–3)199–207
   PubMedGoogle Scholar
• Schroder K., Hertzog P. J., Ravasi T., Hume D. A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004; 75(2)163–189
   PubMed Web of Science ®Google Scholar
• Segura S., Espuelas S., Renedo M. J., Irache J. M. Potential of albumin nanoparticles as carriers for interferon gamma. Drug Dev. Ind. Pharm. 2005; 31(3)271–280
   PubMed Web of Science ®Google Scholar
• Sharifi J., Khawli L. A., Hu P., Li J., Epstein A. L. Generation of human interferon gamma and tumor necrosis factor alpha chimeric TNT-3 fusion proteins. Hybrid. Hybridomics 2002; 21(6)421–432
   PubMedGoogle Scholar
• Shechter Y., Preciado-Patt L., Schreiber G., Fridkin M. Prolonging the half-life of human interferon-α 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7–interferon-α 2. Proc. Natl. Acad. Sci. 2001; 98(3)1212–1217
   PubMedGoogle Scholar
• Short S. M., Paasch B. D., Turner J. H., Weiner N., Daugherty A. L., Mrsny R. J. Percutaneous absorption of biologically-active interferon-gamma in a human skin graft-nude mouse model. Pharm. Res. 1996; 13(7)1020–1027
   PubMedGoogle Scholar
• Smith D. M., Mayhew E., Reszka R., Ito M., O'Malley J. A. Antiviral and antiproliferative properties of liposome-associated human interferon-gamma. J. Interferon Res. 1990; 10(2)153–160
   PubMedGoogle Scholar
• Suginoshita Y., Tabata Y., Moriyasu F., Ikada Y., Chiba T. Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice. J. Pharmacol. Exp. Ther. 2001; 298(2)805–811
   PubMedGoogle Scholar
• Sullivan M. F., Ruemmler P. S., Kalkwarf D. R. Sustained administration of cyclazocine for antagonism of morphine. Drug Alcohol Depend. 1975/76; 1: 415–428
   Google Scholar
• Sullivan S. D., Craxi A., Alberti A., Giuliani G., De Carli C., Wintfeld N., Patel K. K., Green J. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22(4)257–265
   PubMedGoogle Scholar
• Sung C., Nardelli B., Lafleur D. W., Blatter E., Corcoran M., Olsen H. S., Birse C. E., Pickeral O. K., Zhang J., Shah D., Moody G., Gentz S., Beebe L., More P. A. An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J. Interferon Cytokine Res. 2003; 23(1)25–36
   PubMedGoogle Scholar
• ten Hagen T. L., van Vianen W., Bakker-Woudenberg I. A. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. J. Infect. Dis. 1995; 171(2)385–392
   PubMedGoogle Scholar
• ten Hagen T. L., van Vianen W., Savelkoul H. F., Heremans H., Buurman W. A., Bakker-Woudenberg I. A. Involvement of T-cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon. Infect. Immun. 1998; 66(5)1962–1967
   PubMedGoogle Scholar
• Timpane J. Everywhere and then some: physicians making careers in biopharmaceuticals. J. Am. Med. Assoc. 1998; 279(17)1401
   Google Scholar
• Tomlinson E. Impact of the new biologies on the medical and pharmaceutical sciences. J. Pharm. Pharmacol. 1992; 44: 147–159, (suppl. 1)
   PubMed Web of Science ®Google Scholar
• Traub A., Payees B., Reuvery S., Mizrahi A. Interferon-albumin conjugate with conserved biological activity. J. General Virol. 1981; 53: 389–392, (pt2)
   PubMedGoogle Scholar
• Walsh G. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature. Eur. J. Pharm. Sci. 2002; 15(2)135–138
   PubMed Web of Science ®Google Scholar
• Walsh G. Second-generation biopharmaceuticals. Eur. J. Pharm. Biopharm. 2004; 58(2)185–196
   PubMedGoogle Scholar
• Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol. 2005; 23(11)553–558
   PubMed Web of Science ®Google Scholar
• Wang P. Y. Lipid as excipient in sustained release insulin implants. Int. J. Pharm. 1989; 54: 223–230
   Web of Science ®Google Scholar
• Wang Y. S., Youngster S., Grace M., Bausch J., Bordens R., Wyss D. F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 2002; 54: 547–570
   PubMed Web of Science ®Google Scholar
• Weiner N., Williams N., Birch G., Ramachandran C., Shipman C., Jr., Flynn G. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob. Agents Chemother. 1989; 33(8)1217–1221
   PubMed Web of Science ®Google Scholar
• Wills R. J., Dennis S., Spiegel H. E., Gibson D. M., Nadler P. I. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection. Clin. Pharmacol. Ther. 1984; 35: 722–727
   PubMed Web of Science ®Google Scholar
• Xi K., Tabata Y., Uno K., Yoshimoto M., Nishida T., Sokawa Y., Ikada Y. Liver targeting of interferon through pullulan conjugation. Pharm. Res. 1996; 13(12)1846–1850
   PubMed Web of Science ®Google Scholar
• Xu J., Tan L., Goodrum K. J., Kieliszewski M. J. High-yields and extended serum half-life of human interferon alpha2b expressed in tobacco cells as arabinogalactan-protein fusions. Biotechnol. Bioeng. 2007, Feb 27 [Epub ahead of print]
   Google Scholar
• Xu Z. X., Patel I., Joubert P. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamic (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α -2a (IFN α -2a) to healthy subjects. Hepatology 1998; 28: 702, (Suppl.)
   Google Scholar
• Medical Applications of Liposomes, K. Yagi. Scientific Press and Karger, Tokyo 1986
   Google Scholar
• Yamagata Y., Iga K., Ogawa Y. Novel sustained-release dosage forms of proteins using poly glycerol esters of fatty acids. J. Control. Release 2000; 63: 319–329
   PubMed Web of Science ®Google Scholar
• Yang J., Cleland J. L. Factors affecting the in vitro release of recombinant human interferon-γ (rhIFN-γ) from PLGA microspheres. J.Pharm. Sci. 1997; 86(8)908–914
   PubMed Web of Science ®Google Scholar
• Yang L., Yang W., Bi D., Zeng Q. A novel method to prepare highly encapsulated interferon-a 2b containing liposomes for intramuscular sustained release. Eur. J. Pharm. Biopharm. 2006; 64: 9–15
   PubMedGoogle Scholar
• Ye Z. W., Hu Q. H., Liang W. Q. Preparation of interferon-alpha-containing liposomes by the powder bed grinding method. Zhejiang Da. Xue. Xue. Bao. Yi. Xue. Ban. 2002; 31(6)433–436
   PubMedGoogle Scholar
• Younes H. M., Amsden B. G. Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J. Pharm. Sci. 2002; 91(1)2–17
   PubMedGoogle Scholar
• Yu H., Grainger D. W. Modified release of hydrophilic, hydrophobic, and peptide agents from ionized amphiphilic gel networks. J. Control. Release 1995; 34: 117–127
   Web of Science ®Google Scholar
• Zalipsky S., Harris J. M. Introduction to chemistry and biological applications of poly (ethylene) glycol. Poly (ethylene) Glycol Chemistry and Biological Applications, J. M. Harris, S. Zalipsky. American Chemical Society, Washington, DC 1997; 1–13
   Google Scholar
• Zeuzem S., Feinman S. V., Rashenack J., Heathcote E. J., Lai M. Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda M. J. Peginterferon alfa-2a in patients with chronic hepatitis C. New Eng. J. Med. 2000; 343: 1666–1672
   PubMed Web of Science ®Google Scholar
• Zeuzem S., Welsch C., Herman E. Pharmacokinetics of peginterferons. Semin. Liver Dis. 2003; 23–28, Suppl. 1
   PubMedGoogle Scholar
• Zhou S., Deng X., He S., Li X., Jia W., Wei D., Zhang Z., Ma J. Study on biodegradable microspheres containing recombinant interferon-alpha-2a. J. Pharm. Pharmacol. 2002; 54(9)1287–1292
   PubMed Web of Science ®Google Scholar
• Zimmennann U. Cellular drug-carrier systems and their possible targeting. Targeted Drugs, E. P. Goldberg. John Wiley & Sons, New York 1983; 153–200
   Google Scholar